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significant advantage in patients undergoing exclusive 
radiotherapy associated to adjuvant hormone therapy, this 
treatment could improve outcome even in resected patients.  
However, prospective studies on adjuvant hormone therapy 
in patients treated with radical prostatectomy and 
postoperative radiotherapy are lacking. Also comparisons 
between different adjuvant hormone therapies (LH-RH 
analogue vs antiandrogen) are lacking. Aim of this study was 
to evaluate results in patients treated with radical 
prostatectomy followed by postoperative radiotherapy and 
adjuvant hormone therapy and to compare results in patients 
receiving hormone therapy based on LH-RH analogue vs high 
dose Bicalutamide.  
Materials and Methods: Data were collected from two 
different clinical trials in which patients received adjuvant 
hormone therapy, depending on risk categories, with LH-RH 
analogue or high dose Bicalutamide according to the 
preference of urologist and /or patient. Biochemical 
recurrence free survival (PSA >/= 0,2 ng/ml), local control, 
metastasis free survival and overall survival were evaluated 
with the Kaplan-Meier's method. Survival curves were 
compared with logrank test (univariate analysis) or Cox 
Proportional Hazard Method (multivariate analysis), 
considering as covariates: risk class, dose of radiotherapy and 
hormone therapy duration. Patients were classified according 
to NCCN 2014 category risk. 
Results: 140 patients were included in the analysis (pT3-
4:89.0%; pN1:15.8%; R1:85.0%; Gleason score > 7: 35.7%). The 
results are reported in the table below. The multivariated 
analysis confirmed the lack of correlation between type of 
hormone therapy and biochemical recurrence free survival 
(p: 0.250). 
Conclusions: The combination of adjuvant hormone therapy 
and postoperative radiotherapy improves the biochemical 
outcome compared to standard treatment. The efficacy of 
adjuvant therapy seems not related to hormone therapy 
type. Further studies to reduce the toxicity induced by 
hormone therapy in patients treated with radical 
prostatectomy plus radiotherapy are justified. 
   
EP-1250   
Dose-volume analysis of rectal hemorrhage after IMRT for 
prostate cancer 
K. Yasui1, D. Nakamura1, A. Egawa1, T. Yamazaki1, N. 
Hayashi2, K. Takehara3, H. Sakai3, M. Uetani1 
1Nagasaki University Graduate School of Biomedical Sciences, 
Radiological Sciences, Nagasaki, Japan  
2The Japanese Red Cross Nagasaki Genbaku Hospital, 
Radiation oncology, Nagasaki, Japan  
3Nagasaki University Graduate School of Biomedical Sciences, 
Urology, Nagasaki, Japan  
 
Purpose/Objective: To assess the relationship between 
rectal hemorrhage and planned dose-volume histogram (DVH) 
parameters in localized prostate cancer patients with 1-6 
years of follow-up after intensity-modulated radiation 
therapy (IMRT). 
Materials and Methods: Between October 2008 and 
September 2012, 124 patients diagnosed with localized 
prostate cancer (D'Amico classification: low-, intermediate-, 
and high-risk rates: 15%, 23%, and 62%, respectively) were 
treated with IMRT. Among these, 94 patients (76%) received 
hormonal therapy (D'Amico classification: low-, intermediate-
, and high-risk: 42%, 46%, and 95%, respectively). One patient 
was lost to follow-up and excluded from the analysis. 
Therefore, we performed a retrospective analysis of 123 
patients. Rectal hemorrhage was graded according to a 
modification of the CTCAE v4.0 as Grade 1, one untreated 
bleeding episode; Grade 2, two or more bleeding episodes; 
and Grade 3, bleeding requiring one or more transfusions 
and/or Argon plasma coagulation (APC). Three groupings of 
DVH parameters were defined, based on the percentage of 
rectum receiving 70Gy (V70), 60Gy (V60) and 40Gy (V40). 
Associations between DVH groupings or clinical 
characteristics and the incidence of rectal hemorrhage of 
Grade ≥2 were evaluated. 
Results: The median follow-up was 27.8 months (range, 10.2-
56.5 months). The mean age was 70 years (range, 49-82 
years). Fifty-eight patients (47%) were treated to 74 Gy, and 
65 (53%) were treated to 78 Gy. Twenty-two patients (18 %) 
experienced Grade ≥2 rectal hemorrhage. Six patients (5%) 
experienced Grade 3 rectal hemorrhage. No Grade 4 or 5 
rectal hemorrhage was observed. The 3-year Grade 3 rectal 
hemorrhage rate was 6.2%. Freedom from Grade ≥2 rectal 
hemorrhage at 3 years was 81% for patients with rectal V70 60 
40 70 10-15%, V60 20-25%, and V40 40-45%; and 59% for patients 
with rectal V70 15-25%, V60 25-35%, and V40 45-65% (p=0.045). 
Conclusions: The rectal DVH groupings were associated with 
rectal hemorrhage after IMRT. The treatment plan should be 
carefully optimized to minimize dose to the rectum.  
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Purpose/Objective: To evaluate feasibility and acute toxicity 
of retreatment in prostate cancer (PC) patients after 
previous radiotherapy (RT) . 
Materials and Methods: From December 2012 to October 
2014, 10 patients with a prior history of pelvic RT were 
treated with Helical Tomotherapy (HT): acute toxicity was 
evaluable in 7 cases. All patients underwent 18F-choline PET 
and pelvis magnetic resonance imaging scans. Neoadiuvant 
hormone therapy was administred. The prior RT course was 
3rd ESTRO Forum 2015                                                                                                                                         S677 
 
given as radical or adjuvant treatment for PC in 4 and 5 
patients respectively and as neoadjuvant therapy for rectal 
cancer in 1 case. The median dose of prior RT was 70 Gy 
(range 45-76) and the median time between the first and the 
second RT course was 117 months (range 95-219). The total 
dose of retreatment was 50 Gy in 5 patients and 60 Gy in 2 (2 
Gy daily fraction). Patients immobilized with Combifix device 
underwent planning computed tomography (CT) with 3-mm 
slice thickness; they were instructed to receive RT every day 
with an empty rectum and a full bladder. Clinical target 
volume (CTV) was the prostate in 5 and the PET positive 
nodule in 2 patients. Organs at risk (OAR) were: rectum, 
bladder, penile bulb and femoral heads. Planning target 
volume (PTV) was obtained by adding 3-5 mm to the 
corresponding CTV. The parameters used in HT planning 
system were: field width 1 or 2.5 cm, pitch 0.287 and 
modulation factor ranging from 2 to 3. Median duration of 
treatments was 180.7 seconds (range 145-347.8). 
Results: Median follow up was 7 months (range 3-38). All 
patients completed the reirradiation course. PTV median size 
was 66.65 cc (range 7.91 – 114.26). The cumulative mean 
dose (D mean) to the rectum ranged from 37.87 to 73.83 Gy 
and the cumulative rectal maximum dose (D max) ranged 
from 112.66 to 119.85 Gy. The cumulative D mean to the 
bladder ranged between 19.84 and 83.79 Gy; cumulative D 
max ranged from 93.99 to 126.3 Gy. When total dose was 50 
Gy, the OAR dose volume constraints were: V10< 40% and 
V25<10% for rectum; V10<20%, V25<10% and V44<2% for 
bladder. When total dose was 60 Gy the constraints were: 
V10<30% and V30<1% for rectum and V10<15%, V30<10% and 
V50<5% for bladder. Acute grade 2 genitourinary toxicity was 
observed in 3 patients and grade 2 gastrointestinal toxicity in 
1 patient. Three months after retreatment all patients had 
early PSA decrease; only 2 patients experienced biochemical 
relapse due to pelvic nodal recurrence. One patient died for 
bladder cancer.  
Conclusions: PC patients benefit from salvage reirradiation 
with HT. The treatment was feasible and well tolerated, with 
low rates of acute toxicity. Longer follow up is required to 
confirm retreatment safety and evaluate late toxicity. 
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Purpose/Objective: Even if many advances have been done 
in cancer care, clinical choices are based on evidence-based 
guidelines, resulted from large randomized trials often, and 
applicable only to population subset. Need of 'tailored 
treatment' can require specialized Decision Support System 
(DSS). Therefore, creation of large, and heterogeneous 
databases, could implement and validate DSS based on 
predictive models. In order to share the same meaning 
between people involved in the project, an ontology need to 
be created and shared. Our aim is to build a prostate cancer 
ontology able to represent a list of the main concepts 
involved in this semantic domain and how those concepts are 
related, by a graph. 
Materials and Methods: We built ontology starting from a 
well-defined data collection model, able to collect, 
standardize and organize concepts related with prostate 
cancer patients. These features were organized according 
three different levels. The first, Registry level, includes all 
general epidemiological information (age, gender, e.g.). The 
second, Procedure tier, includes information about treatment 
and toxicities, and outcome evaluation. The last, Research 
level, includes clinical, imaging and Quality of Life 
information for advanced research projects. Relationships 
between concepts have been added as last step. The so built 
ontology describes each of these concepts with a unique 
reference, preferably mapped to a published coding system 
(e.g. NCI Thesaurus, CTCAE).  
Results: Building an ontology is a good strategy to 
standardize data and procedure and create a consistent 
dataset. We selected more than 200 variables related with 
prostate cancer. The three data storing tiers were used to 
classify all the information to easily develop queries 
depending on the analysis different (epidemiological, 
toxicity, outcomes e.g.). Many concepts can be shared with 
ontologies related other cancer sites (general idea of 
toxicities, TNM, etc.) while others are prostate specific (PSA, 
etc.). We decided to adopt a trade-off between the formal 
explication of the ontology and the effective usability of it: 
even if a formal ontology is a powerful tool to allow 
automatic inference and represent in a not-ambiguous way a 
semantic, it is hard to be handled and properly validated.  
Conclusions: Sharing and combining multiple dataset, 
through structural collaboration between different groups, 
are the basis to generate large databases. Computer Science 
allows us to share concepts in a not ambiguous way in order 
to do that, by using ontologies and related languages. 
Through an ontology creation we obtained a standardized and 
organized dataset, easy to be shared and understood, not 
ambiguous, mapped on most common international standards 
and suitable to create predictive models which complement 
existing consensus or guidelines, moving from prescription by 
consensus to prescription by numbers.  
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Purpose/Objective: The aim of this study is to evaluate the 
changes in bladder doses during the volumetric modulated 
arc therapy (VMAT) treatment of prostate cancer patients 
using weekly cone beam computed tomography (CBCT) data. 
Materials and Methods: Ten consecutive patients with 
prostate cancer treated by radical RT were considered. For 
each patient, pre-treatment CBCT performed on a weekly 
basis were analyzed by using two different methods of target 
localization (intraprostatic fiducials and bony anatomy). To 
evaluate the changes in bladder doses; organs of interest 
were contoured on each weekly treatment CBCT data set and 
the images, along with the contours, were registered to the 
original planning CT. The replanning was made on planning 
CT using contours transfered from CBCT for two different 
